Dear Editor, The staff report on Medtronic's influence on Infuse clinical studies published in October 2012 is very interesting to read 1. Especially, the magnitude of the influence of a sponsoring industry is surprising. Of course, Medtronic did not agree with the findings 2. However, if only half was true it still remained amazing. I am convinced that these findings were not restricted to Medtronic. I assume that the results of the investigation of the Committee on Finance can be extrapolated to many companies dealing with medical devices, implants or drugs. The main goal of every company is to make profit to regain at least the investments to develop a new product, and preferentially to meet the expectations of the investors.
展开▼
